Press Releases

InVivo Therapeutics Sponsors 2013 RISE Above Paralysis Gala

Published: March 14, 2013

CAMBRIDGE, Mass. (March 14, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company has renewed its support for the Greater Boston Chapter of the National Spinal Cord Injury Association (NSCIA), a non-profit organization that offers programs and services to those with spinal cord injury and disease. InVivo will serve as a Premier sponsor at the RISE Above Paralysis Gala this Saturday, March 16, 2013, an annual event hosted by the Greater Boston Chapter of the NSCIA. The evening will bring […]

View Article
InVivo Therapeutics Reports 2012 Financial Results, Provides Business Update

Published: March 13, 2013

CAMBRIDGE, Mass. (March 13, 2013) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today reported financial results for the year ended December 31, 2012 and provided a business update. InVivo has pioneered a new treatment platform utilizing a variety of biocompatible polymer-based devices to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving functional recovery and prognosis after a traumatic SCI. Today there is no effective treatment for the spinal cord for paralysis caused by SCIs, […]

View Article
InVivo Therapeutics Submits Updated IDE to FDA to Begin Spinal Cord Injury Human Study

Published: February 28, 2013

CAMBRIDGE, Mass. (February 28, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced the Company has submitted an updated Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) requesting permission to begin human studies in order to test its biopolymer scaffolding for the treatment of acute SCI. The updated IDE submission is in response to exchanges since InVivo’s April 12, 2012 meeting with the FDA. The filing contains additional information regarding the manufacturing and pre-clinical testing of the scaffolding device. […]

View Article
InVivo Therapeutics Calls for Papers for 2nd Annual Langer Summit on Neurotrauma

Published: February 7, 2013

CAMBRIDGE, Mass. (February 7, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced the 2nd Annual Langer Summit on Neurotrauma, taking place on Cape Cod in North Falmouth, MA on July 12 – 14, 2013. The Company is inviting papers in the fields of neurotrauma and SCI, and will announce the recipient of a $50,000 grant that will be given to a researcher developing novel biomaterial treatments for neurotrauma at the Summit. The award is intended to stimulate innovation and cutting-edge ideas in […]

View Article
InVivo Therapeutics to Present at 5th Annual Biotech Showcase

Published: January 4, 2013

CAMBRIDGE, Mass. (January 4, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that Chief Executive Officer Frank Reynolds will present recent updates to potential investors during Biotech Showcase 2013. The annual conference is scheduled for January 7-9th at the Parc 55 Wyndham in San Francisco. Reynolds is scheduled to participate in a panel titled ‘Spinal Cord Injury: Investment Opportunities and Challenges in an Area With Unmet Medical Needs’ on Wednesday, January 9th at 8:00am PST. The panel will be followed by a […]

View Article
InVivo Therapeutics Co-Founder Robert S. Langer to be Awarded National Medal of Technology and Innovation by President Barack Obama at the White House in Early 2013

Published: January 3, 2013

CAMBRIDGE, Mass. (January 3, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today congratulates Robert S. Langer, ScD, InVivo co-founder and member of the Company’s scientific advisory board, on receiving the National Medal of Technology and Innovation. President Barack Obama will present the award to Dr. Langer, who also won the National Medal of Science in 2006, at a White House ceremony in early 2013. Dr. Langer, the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT), is among 23 renowned […]

View Article
InVivo’s Jason Fowler Wins 2012 Ironman World Championship

Published: December 24, 2012

CAMBRIDGE, Mass. (December 24, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today congratulates InVivo Therapeutics’ sponsored athlete Jason Fowler on winning the 2012 Ironman 70.3 World Triathlon Championships in Las Vegas, NV. As a nationally ranked amateur motocross racer, Fowler was paralyzed from the chest down at the age of 17 as the result of a motorcycle accident. Following his accident Fowler remained an avid athlete, and has since completed 150 road races, 30 marathons, and 29 triathlons, and has won several local […]

View Article
Biogen Executive Kenneth DiPietro Joins InVivo Therapeutics Board of Directors

Published: December 18, 2012

CAMBRIDGE, Mass. (December 18, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that Kenneth DiPietro, Executive Vice President Human Resources at Biogen Idec, has joined InVivo’s Board of Directors. DiPietro has also been appointed as Chair of the Board’s Governance, Nominating and Compensation committee. InVivo has pioneered a new technology platform utilizing a variety of biocompatible polymer-based devices to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving functional recovery and prognosis after a […]

View Article
InVivo Therapeutics Requests Humanitarian Use Device Designation with FDA

Published: December 14, 2012

CAMBRIDGE, Mass. (December 14, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company has filed a request with the U.S. Food and Drug Administration (FDA) for Humanitarian Use Device (HUD) designation for its biopolymer scaffolding product. InVivo is currently working with the FDA on the final steps to seek approval to begin a clinical trial of the scaffolding in acute SCI in early 2013. Devices eligible for HUD designation are developed to treat rare diseases or conditions. InVivo has requested […]

View Article
InVivo Therapeutics Reports Third Quarter 2012 Financial Results, Provides Business Update

Published: November 14, 2012

CAMBRIDGE, Mass. (November 14, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today reported the financial results for the three and nine months ended September 30, 2012 and provided a business update. InVivo has pioneered a new treatment platform utilizing a variety of biocompatible polymer-based devices to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving functional recovery and prognosis after a traumatic spinal cord injury. Today there is no effective treatment for the spinal cord […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.